

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

RESULTS OF ANNUAL GENERAL MEETING HELD ON 15 MAY 2024

The Board of Directors (the “**Board**”) of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the “**Company**”) wishes to announce that at the Annual General Meeting (“**AGM**”) of the Company held on 15 May 2024, all resolutions relating to the matters set out in the Notice of AGM dated 30 April 2024 (superseding the Notice of AGM dated 29 March 2024) were passed.

Resolution(s) (poll voting)

The results of the poll on each of the resolutions 1 to 17 put to vote at the AGM are set out below. All the resolutions 1 to 17 were duly passed at the AGM.

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
1	To consider and approve the Chairman's Report for FY2023.	346918866	346918166	100.000	700	0.000	0	0.000
2	To consider and approve the Board of Directors' Report for FY2023.	346918866	346918166	100.000	700	0.000	0	0.000
3	To consider and approve the Supervisory Committee's Report for FY2023.	346918866	346918166	100.000	700	0.000	0	0.000
		346918866	346918166	100.000	700	0.000	0	0.000

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
4	To consider and approve the Financial Report and Audit Report for FY2023 audited by CAC Certified Public Accountants LLP (中审华会计师事务所) and Foo Kon Tan LLP HLB Singapore and reviewed by the Audit Committee of the Company.							
5	To consider and approve the scheme of profit distribution policy of the Company for FY2023.	346918866	346908166	99.997	700	0.000	10000	0.003
6	To consider and approve the remuneration of S\$55,000 for independent director Mr. Liew Yoke Pheng Joseph (刘育彬) for FY2023.	346918866	346918166	100.000	700	0.000	0	0.000
7	To consider and approve the remuneration of RMB60,000 for independent director Ms. Li Qing (李清) for FY2023.	346918866	346918166	100.000	700	0.000	0	0.000

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
8	To consider and approve the remuneration of S\$4,600 for independent director Mr. Yeo Guat Kwang (杨木光) for FY2023 (specifically, for the period from 28 November 2023 to 31 December 2023).	346918866	346918166	100.000	700	0.000	0	0.000
9	To consider and approve the remuneration of S\$50,400 for independent director Mr. Zhu Haifeng (朱海峰) for FY2023 (specifically, for the period from 1 January 2023 to 28 November 2023).	346918866	346918166	100.000	700	0.000	0	0.000
10	To consider and approve the aggregate remuneration for directors of the Company for FY2023.	346918866	346917866	100.000	700	0.000	300	0.000
11	To consider and approve the	346918866	346917866	100.000	700	0.000	300	0.000

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	aggregate remuneration for members of the Supervisory Committee for FY2023.							
12	To consider and approve the proposed amendments to the Articles of Association of the Company and the application for changes in the industrial and commercial registration.	346918866	346918166	100.000	700	0.000	0	0.000
13	To consider and approve the proposed amendments to the Independent Directors System (独立董事制度) of the Company.	346918866	344418166	99.279	700	0.000	250000 0	0.721
14	To consider and approve the proposed renewal of the shareholders' mandate for interested person transactions.	21063338	21062638	99.997	700	0.003	0	0.000
15	To consider and	346918866	346918166	100.000	700	0.000	0	0.000

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	approve the proposed lines of credit granted to the Company up to an aggregate limit of RMB11,680 million.							
16	To consider and approve the proposed continuous provision of guarantee for an amount of up to RMB1,900 million by the Company for its wholly-owned subsidiary, Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司).	346918866	346904766	99.996	4000	0.001	10100	0.003
17	To consider and approve the proposed continuous provision of an entrusted loan (委托贷款) of RMB1,200 million by the Company to its wholly-owned subsidiary, Tianjin Zhongxin Medicine Co., Ltd. (天津中新医	346918866	346904866	99.996	14000	0.004	0	0.000

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	药有限公司).							

Resolution(s) (cumulative voting)

The result of the resolution 18 put to vote by way of cumulative voting at the AGM is set out below. The resolution 18 was duly passed at the AGM, and Mr. Zhong Ming (钟铭) (“**Mr. Zhong**”) was successfully appointed as an Independent Director of the Company with effect from the date of the AGM.

No.	Resolution(s) relating to:	Total number of shares represented by votes for and against the relevant resolution	Number of votes for the relevant resolution	As a percentage of total number of votes for and against the resolution (%)
To consider and approve the proposed appointment of one (1) independent director of the Company				
18	To consider and approve the proposed appointment of Mr. Zhong Ming (钟 铭) as an independent director of the Company.	346918866	346607667	100.000

Details of parties who are required to abstain from voting on any resolution

The following director of the Company had abstained from voting on resolution 10 in relation to the aggregate remuneration for directors of the Company for FY2023:

Name	Number of shares held
Zhou Hong	23,800 Restricted A-shares

Pursuant to Rule 919 of the Listing Manual, Tianjin Pharmaceutical Holdings Co., Ltd. (“**TPH**”) (being the controlling shareholder of the Company) which holds 325,855,528 A-shares in the Company, and Tianjin Pharmaceutical (Singapore) International Investment Pte. Ltd. (being the wholly-owned subsidiary of TPH) which holds 5,265,000 S-shares in the Company, had abstained from voting on resolution 14 in relation to the proposed renewal of the shareholders’ mandate for interested person transactions. Further, Jinhushen Biological Medical Science and Technology Co., Ltd (津沪深生物医药科技有限公司) (being the controlling shareholder of TPH) which holds 4,497 A-shares in the Company, had also abstained from voting on resolution

14. In addition, TPH and its associates did not accept nominations as proxies or otherwise for voting on resolution 14 at the AGM, unless they were given specific instructions by independent shareholder(s) as to how to vote.

Note of appreciation to the resigning Director

Ms. Li Qing (李清) (“**Ms. Li**”), an Independent and Non-Executive Director, retired as a Director of the Company at the conclusion of the AGM as she did not seek re-election. Ms. Li was previously Chairman of the Nomination Committee and a member of the Audit Committee. The Board would like to express its appreciation to Ms. Li for her invaluable contribution and insightful guidance to the Company during her tenure. Please also refer to the separate announcement made by the Company in respect of Ms. Li’s retirement as a Director of the Company as required under Rule 704(7) of the Listing Manual.

Appointment of Director to the Audit Committee

Following the conclusion of the AGM, the Company wishes to announce that Mr. Zhong, who has been appointed as an Independent Director of the Company, will be appointed as a member of the Audit Committee. He is considered by the Board to be independent for the purposes of Rule 704(8) of the Listing Manual. Please also refer to the separate announcement made by the Company in respect of Mr. Zhong’s appointment as a Director of the Company as required under Rule 704(7) of the Listing Manual.

Consequently, the composition of the Board shall be as follows:

Board of Directors

Chairman	:	Ms. Zhang Mingrui
Executive Directors	:	Mr. Guo Min Ms. Wang Lei Mr. Zhou Hong Mr. Shang Mingjie
Non-Executive and Non-Independent Directors	:	Ms. Zhang Mingrui Ms. Mao Weiwen
Independent and Non-Executive Director	:	Mr. Yeo Guat Kwang (Lead Independent Director) Mr. Liew Yoke Pheng Joseph Mr. Zhong Ming

Audit Committee

Chairman	:	Mr. Liew Yoke Pheng Joseph
Members	:	Mr. Yeo Guat Kwang Mr. Zhong Ming

Nomination Committee

Chairman	:	Mr. Zhong Ming
Members	:	Mr. Guo Min Mr. Yeo Guat Kwang

Remuneration Committee

Chairman : Mr. Yeo Guat Kwang

Members : Ms. Mao Weiwen
Mr. Liew Yoke Pheng Joseph

Strategy Committee

Chairman : Ms. Zhang Mingrui

Members : Mr. Guo Min
Ms. Wang Lei

Scrutineer

Pursuant to Rule 704(16) of the Listing Manual, Drewcorp Services Pte Ltd acted as the Company's scrutineer for the AGM.

BY ORDER OF THE BOARD

Jiao Yan
Secretary to the Board of Directors
15 May 2024